What is NDC 72205-389?

72205-389 is the product NDC for Deferasirox, Deferasirox 125 mg/1 tablet, for suspension, listed with the FDA by Novadoz Pharmaceuticals LLC. It has 4 package NDCs, shown above in 10- and 11-digit form.

Novadoz Pharmaceuticals LLC, NDC labeler code 72205. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Deferasirox?

75 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Deferasirox NDC 72205-389 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-389Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0389Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
72205-389-01	7220503890172205038901	30 TABLET, FOR SUSPENSION in 1 BOTTLE (72205-389-01)Marketed from Jan 29, 2026
72205-389-02	7220503890272205038902	90 TABLET, FOR SUSPENSION in 1 BOTTLE (72205-389-02)Marketed from Jan 29, 2026
72205-389-03	7220503890372205038903	1000 TABLET, FOR SUSPENSION in 1 BOTTLE (72205-389-03)Marketed from Jan 29, 2026
72205-389-05	7220503890572205038905	10 BLISTER PACK in 1 CARTON (72205-389-05) / 10 TABLET, FOR SUSPENSION in 1 BLISTER PACKMarketed from Jan 29, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Deferasirox
Generic name (nonproprietary): deferasirox
Active ingredients: Deferasirox — 125 mg/1
Dosage form: Tablet, For suspension
Route: Oral
Labeler: Novadoz Pharmaceuticals LLCNDC labeler code 72205
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209878
Marketing start: Nov 20, 2019
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 1A2 Inhibitors (Mechanism)Cytochrome P450 2C8 Inhibitors (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Iron Chelating Activity (Mechanism)
Identifiers: Product ID 72205-389_a03c7657-fdca-4acb-ad82-c24680e90eaeSPL ID a03c7657-fdca-4acb-ad82-c24680e90eaeSPL set ID a03c7657-fdca-4acb-ad82-c24680e90eaeRxCUI 597768, 597770, 597772UNII V8G4MOF2V9UPC 0372205389014, 0372205391017, 0372205390010
Pharmacologic class: Iron Chelator

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N472205038901 followed by a unit qualifier and the quantity

Package 72205-0389-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 12, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Deferasirox tablets for oral suspension are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets for oral suspension are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of deferasirox when administered with other iron chelation therapy have not been established. ( 1.3 ) 1.1 Treatment of Chronic Iron…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72205-389

What is NDC 72205-389?: 72205-389 is the product NDC for Deferasirox, Deferasirox 125 mg/1 tablet, for suspension, listed with the FDA by Novadoz Pharmaceuticals LLC. It has 4 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Deferasirox.
What is the active ingredient?: Deferasirox.
Who is the labeler?: Novadoz Pharmaceuticals LLC, NDC labeler code 72205. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Deferasirox?: 75 other product NDCs are listed under this name. See all Deferasirox NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Deferasirox NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Deferasirox	Deferasirox 360 mg/1	TabletOral	AvKARE	73190-052	73190-0052-30
Deferasirox	Deferasirox 90 mg/1	GranuleOral	Aurobindo Pharma Limited	59651-447	59651-0447-30
Deferasirox	Deferasirox 180 mg/1	GranuleOral	Aurobindo Pharma Limited	59651-448	59651-0448-30
Deferasirox	Deferasirox 360 mg/1	GranuleOral	Aurobindo Pharma Limited	59651-449	59651-0449-30
Deferasirox	Deferasirox 125 mg/1	Tablet, For suspensionOral	Teva Pharmaceuticals, Inc.	0480-7011	00480-7011-56
Deferasirox	Deferasirox 250 mg/1	Tablet, For suspensionOral	Teva Pharmaceuticals, Inc.	0480-7012	00480-7012-56
Deferasirox	Deferasirox 500 mg/1	Tablet, For suspensionOral	Teva Pharmaceuticals, Inc.	0480-7013	00480-7013-56
Deferasirox	Deferasirox 360 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	59651-412	59651-0412-30
Deferasirox	Deferasirox 90 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	59651-410	59651-0410-30
Deferasirox	Deferasirox 180 mg/1	Tablet, Film coatedOral	Aurobindo Pharma Limited	59651-411	59651-0411-30

All 76 Deferasirox NDCs

Other NDCs under ANDA 209878

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209878
Product	Strength	Form · route	Labeler	Product NDC
Deferasirox	Deferasirox 500 mg/1	Tablet, For suspensionOral	Dr. Reddy's Laboratories Inc	43598-854
Deferasirox	Deferasirox 125 mg/1	Tablet, For suspensionOral	Dr. Reddy's Laboratories Inc	43598-855
Deferasirox	Deferasirox 250 mg/1	Tablet, For suspensionOral	Dr. Reddy's Laboratories Inc	43598-856
Deferasirox	Deferasirox 125 mg/1	Tablet, For suspensionOral	MSN LABORATORIES PRIVATE LIMITED	69539-021
Deferasirox	Deferasirox 250 mg/1	Tablet, For suspensionOral	MSN LABORATORIES PRIVATE LIMITED	69539-022
Deferasirox	Deferasirox 500 mg/1	Tablet, For suspensionOral	MSN LABORATORIES PRIVATE LIMITED	69539-023
Deferasirox	Deferasirox 250 mg/1	Tablet, For suspensionOral	Novadoz Pharmaceuticals LLC	72205-390
Deferasirox	Deferasirox 500 mg/1	Tablet, For suspensionOral	Novadoz Pharmaceuticals LLC	72205-391